A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Condition:   Relapsing Remitting Multiple SclerosisInterventions:   Drug: Glatiramer acetate (GA);   Other: PlaceboSponsor:   Teva Pharmaceutical IndustriesActive, not recruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials